Trial Profile

A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2025 According to a Rhythm Pharmaceuticals media release, data from this study will be presented at The Endocrine Societys Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
07 May 2025 According to a Rhythm Pharmaceuticals media release, Announce topline data from the bivamelagon Phase 2 trial in acquired HO in the third quarter of 2025.
26 Feb 2025 According to Rhythm Pharmaceuticals media release, company announced completion of enrollment in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com